Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03347370 Completed - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis

PERFECT
Start date: November 27, 2017
Phase:
Study type: Observational

The purpose of this study is to investigate the safety of subcutaneous (SC) interferon beta therapies with regard to frequency of injection site reactions (ISR) and flu-like symptoms (FLS) as reported by the relapsing-remitting multiple sclerosis (RRMS) participants.

NCT ID: NCT03346668 Completed - Clinical trials for Frontal Fibrosing Alopecia

Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

Start date: January 28, 2016
Phase: Early Phase 1
Study type: Interventional

This study will serve as a pilot study to determine the efficacy and safety of topical gabapentin in the treatment of symptomatic scarring alopecia.

NCT ID: NCT03346616 Completed - SMS Clinical Trials

Text4Peds: Short Message Service Evaluating Medical Student Education

Start date: May 2, 2016
Phase: N/A
Study type: Interventional

In this study, third year medical students on the pediatric clerkship will be randomized to receive either only written educational material (review journal articles) or written educational material plus daily text messages consisting of board style questions with online answers. The students' performance on the National Board of Medical Examiners (NBME) Pediatric Subject Evaluation will be compared between the two groups.

NCT ID: NCT03346330 Completed - Clinical trials for Healthy, Peripheral Neuropathic Pain

Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food-effect of TRK-750

Start date: November 21, 2017
Phase: Phase 1
Study type: Interventional

This is an exploratory, randomised, double-blind, placebo-controlled, Phase I study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food-effect of single and multiple, ascending oral doses of TRK-750 in healthy adults and patients with peripheral neuropathic pain.

NCT ID: NCT03346057 Completed - Clinical trials for Reversal of Neuromuscular Blockade

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

Start date: December 20, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this trial is to evaluate the safety of sugammadex for the reversal of neuromuscular blockade (NMB) induced by neuromuscular blockade agents (NMBA) rocuronium or vecuronium in adult American Society of Anesthesiologists (ASA) Physical Status Class 3 and 4 participants. The primary objectives of the study are to characterize the incidence of treatment emergent sinus bradycardia, treatment emergent sinus tachycardia, or other treatment emergent cardiac arrhythmias after administration of sugammadex and to evaluate the general safety of sugammadex in a population of ASA Class 3 and 4 participants in a surgical setting.

NCT ID: NCT03345810 Completed - Clinical trials for Non Small Cell Lung Cancer

Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

DURATION
Start date: December 14, 2017
Phase: Phase 2
Study type: Interventional

AIO-YMO/TRK-0416 (DURATION) is a open-label, treatment stratified and randomized phase II study of Durvalumab, frail or elderly patients with metastatic non-squamous NSCLC with no targetable molecular alterations (EGFRwt; ALKtransl-) and not amenable to cisplatinum-based standard-combination chemotherapy but eligible for at-least mono-chemotherapy with gemcitabine or vinorelbine.

NCT ID: NCT03345316 Completed - Clinical trials for Children Under 18 Years Old With Kidney Disease

Study of FFI-1010 in Pediatric Kidney Disease

Start date: November 1, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is revealing that the ratio of creatinine clearance (Ccr) to inulin clearance (Cin) measuring at the same time is more than 1.2.

NCT ID: NCT03345082 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Start date: November 6, 2017
Phase: Phase 2
Study type: Interventional

A multicentre, randomised, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.

NCT ID: NCT03344458 Completed - Clinical trials for Endocrine System Diseases

A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

enliGHten
Start date: December 19, 2017
Phase: Phase 3
Study type: Interventional

A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. Approximately 300 children (males and females) with GHD will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Poland, Bulgaria, Ukraine, Armenia, Russia and Australia.

NCT ID: NCT03344159 Completed - Clinical trials for Pulmonary Arterial Hypertension

Spironolactone Therapy in Chronic Stable Right HF Trial

STAR-HF
Start date: April 1, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in patients with chronic right heart failure.